Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. [electronic resource]
Producer: 20030903Description: 847-58 p. digitalISSN:- 1533-4406
- Adult
- Aged
- Azathioprine -- adverse effects
- Coronary Disease -- diagnostic imaging
- Coronary Vessels -- diagnostic imaging
- Cyclosporine -- therapeutic use
- Cytomegalovirus Infections -- epidemiology
- Double-Blind Method
- Drug Therapy, Combination
- Everolimus
- Female
- Graft Rejection -- physiopathology
- Heart Transplantation -- adverse effects
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors -- therapeutic use
- Immunosuppressive Agents -- adverse effects
- Lipids -- blood
- Male
- Middle Aged
- Reoperation
- Sirolimus -- adverse effects
- Transplantation, Homologous
- Tunica Intima -- pathology
- Ultrasonography, Interventional
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.